Introduction
Gene therapy of disorders of the hematopoietic system is widely limited by unstable gene expression in hematopoietic organs. In recent trials on retrovirus-mediated transfer of the human multidrug resistance (MDR1) gene to hematopoietic cells of cancer patients, the levels of proviral cDNA present in peripheral blood after several weeks or months were generally low or undetectable. [1] [2] [3] [4] These studies were aimed at protecting hematopoietic cells from adverse effects of chemotherapy such as leukocytopenia. In general, the frequency of cells with integrated proviral sequences in blood or bone marrow (frequently below 0.05-1.0% in gene replacement trials) is strikingly lower than the percentage of transduced cells which was improved upon addition of leukemia inhibitory factor and interleukin-11. Furthermore, the CAFC frequency among cells treated with these cytokines was increased as compared with widely used cocktails containing interleukin-3, interleukin-6 and SCF. Rhodamine-123 appeared to be a particularly sensitive indicator for differentiation of PBPC. For analysis of gene transfer, amphotropic retroviruses conferring an MDR1 cDNA were added repeatedly for 6 days to cytokine-treated PBPC stroma-free cultures. Proviral cDNA was detected by polymerase chain reaction in 68% of cobblestone areas derived from CD34
+ HLA-DR low cells that had been exposed to Flt-3 ligand, interleukin-6 and SCF. In summary, conditions were identified that facilitate efficient transduction of early PBPC with amphotropic retroviruses while preserving a primitive phenotype for extended periods. Gene Therapy (2001) 8, 687-696. in grafts by the time of transplantation. Thus, transduced hematopoietic stem cells contribute poorly to repopulation of the patient's bone marrow even if reinfused after myeloablative chemotherapy.
In principle, pluripotent hematopoietic stem cells are ideal targets for gene transfer because they have the unique potential of self-renewal and differentiation into all hematopoietic lineages. Since retrovirally transferred sequences are stably integrated in the genome of host cells, retroviral transduction of hematopoietic stem cells should ensure life-long gene expression. Conversely, the life span of the progeny of more differentiated progenitor cells is restricted because they lack self-renewal capacity.
Within the hematopoietic progenitor/stem cell compartment a subpopulation expressing the CD34 antigen, but low levels of HLA-DR or CD38 consists of very early, primitive cells. 5, 6 In addition, pluripotent stem cells accumulate only low amounts of rhodamine-123 (Rho) due to active efflux by P-glycoprotein, the product of the MDR1 gene (Rho low phenotype). 7-9 P-glycoprotein is also expressed by some lymphocytes, but not by myeloid or erythroid cells. 10 ,11 P-glycoprotein protects cells from tures (LTC), which have the morphological appearance of cobblestone areas. The number of cobblestone area forming-cells (CAFC) is closely correlated with the number of bone marrow repopulating cells following transplantation. 13, 14 Transduction of pluripotent hematopoietic stem cells with retroviruses has been difficult to perform. These cells are physiologically quiescent while cell proliferation is required for integration of retroviral sequences. 15, 16 For activation of primitive hematopoietic cells, growth factors have been employed in gene transfer protocols, either produced by stroma cells from bone marrow, or by supplementation of culture medium with recombinant cytokines. A combination containing interleukin (IL)-3, IL-6 and SCF has been applied in many preclinical and clinical studies. 17 More recently, Flt-3 ligand (FL), a growth factor that stimulates quiescent, primitive cells, has been added. 18, 19 Recent studies have shown that primitive cord blood cells can be expanded ex vivo by FL in combination with other factors. 20 However, while growth factors facilitate expansion in culture they may reduce the ability of stem cells to repopulate bone marrow. [21] [22] [23] Correspondingly, retrovirus-mediated transduction in the presence of growth factors can lead to lowlevel engraftment. 24 We have hypothesized that culture conditions widely used for transduction of hematopoietic cells may lead to a loss of a primitive cell phenotype. Primitive progenitor cells (CD34 + HLA-DR low Rho low ), isolated from peripheral blood progenitor cell (PBPC) collections, were investigated for changes of an immature phenotype during stimulation with cytokines. IL-3-containing growth factor combinations were found to differentiate primitive PBPC to a Rho high phenotype, which was not observed with several other growth factors. We have analyzed cytokine combinations without IL-3 with respect to proliferative stimulation of CD34 + HLA-DR low Rho low PBPC. Thereby, conditions were identified under which these cells are efficiently transduced while maintaining a primitive phenotype for extended periods.
Figure 1 Immunomagnetic separation of primitive progenitor cells. Hematopoietic cells from stem cell collections were separated immunomagnetically as described in the text. After enrichment of CD34 + cells, HLA-DR-expressing cells were depleted. The isolated cells were then restained with phycoerythrin-labeled monoclonal antibodies to CD34, and FITCconjugated antibodies to HLA-DR. Antigen expression as determined by flow cytometry is shown (a) in unseparated cells and (b) in the isolated cell population in a typical

Results
Isolation of primitive hematopoietic progenitor cells Following mobilization into peripheral blood, early hematopoietic progenitor cells were isolated from stem cell collections by immunomagnetic enrichment of cells expressing the CD34 antigen and depletion of HLA-DRexpressing cells. As depicted in Figure 1 a, less than 0.15% of unseparated cells expressed CD34, and low or undetectable amounts of HLA-DR. Figure 1b shows enrichment of cells with this primitive phenotype (up to 94.1%, mean 60.6% ± 20.4% in 35 independent experiments). The entire isolated cell population displayed low rhodamine-123 accumulation (Figure 1c) . Active extrusion of rhodamine-123 was confirmed by reversal with verapamil, a P-glycoprotein inhibitor. Preservation of rhodamine-123 efflux in stroma-free suspension cultures To investigate whether this phenotype was stable in tissue culture, the immunoseparated cells were grown in suspension cultures supplemented with growth factors. As shown in Figure 2 , exposure to IL-3 as a single growth factor for 5 days caused them to accumulate high amounts of rhodamine-123 (Rho high phenotype). Markedly decreased numbers of Rho low cells were already observed after 2 days in culture (not shown). In contrast, supplementation with other single cytokines such as SCF, IL-6 or FL preserved the Rho low phenotype in the majority of cells. If cells were maintained without growth factors, only very few survived a 5-day period (not shown).
Next, we investigated combinations of growth factors ( Figure 2 ). Cells were transformed into a Rho high phenotype if grown in the presence of IL-3, IL-6 and SCF. This was due to IL-3, because the latter two cytokines preserved rhodamine-123 extrusion if IL-3 was not present. The number of Rho low cells was only moderately higher if FL was added to the three factors. If IL-3 was omitted, however, more than 50% of cells grown in the presence of FL, IL-6 and SCF, maintained rhodamine-123 efflux. Addition of leukemia inhibitory factor (LIF) and IL-11 to the latter cytokine combination gave almost identical results (Figure 2 ). In the absence of IL-3, the Rho low phenotype was stable for at least 7 days (not shown). A 5-day culture period was chosen for further analyses.
Interestingly, the respective cytokines affected rhodamine-123 accumulation more than surface antigen expression. Neither CD34 nor HLA-DR levels differed Gene Therapy While the isolated progenitor cell population was efficiently expanded in the presence of IL-3-containing growth factor combinations (up to nine-fold), FL combined with IL-6 and SCF also increased the total cell numbers, but to a lesser extent (2.5-fold) ( Figure 4 ). Addition of LIF or IL-11 to the latter cytokine cocktail gave similar results. Cell growth was poor when single growth factors other than IL-3 were used ( Figure 4 ).
Increased cell numbers do not necessarily mean that the entire population is induced to proliferate. The rate of cell divisions was therefore studied with a fluorescent dye. PKH-26, which is covalently linked to the plasma membrane, is equally distributed between the two daughter cells during each cell division. Hence, each cell division is indicated by a 50% reduction of cellular fluorescence. When used as single factors, IL-6, SCF or FL caused only a small proportion cells to divide ( Figure 5 ). IL-6 combined with SCF was slightly superior, while FL displayed strong synergistic effects with IL-6 and SCF. Only a small proportion of cells failed to divide when grown in the presence of FL, IL-6 and SCF. FL acted in a dose-dependent fashion: growth stimulation was observed at concentrations of 2 ng/ml and higher, with a maximal effect at 100 ng/ml or above (data not shown).
Expectedly, IL-3 exerted profound growth stimulatory effects, activating CD34
+ HLA-DR low cells to divide at least twice or three times. This stimulation was further augmented when IL-3 was combined with IL-6 and SCF +/− FL ( Figure 5 ). These findings were confirmed by analysis of the cell cycle status of CD34 + HLA-DR low cells. By the time of immunomagnetic cell separation, the population was quiescent with less than 2.5% in S-or G 2 /M-phase ( Figure 6 ). This number was increased to 23% after 5 days if cells were stimulated with FL, IL-6 and SCF, and to 29% in the presence of IL-3, IL-6 and SCF. Omission of either FL or IL-3 resulted in lower numbers of cells in Sor G 2 /M-phase. 
HLA-DR
low cells were first maintained for 5 days in suspension cultures, then harvested, counted and transferred in limiting dilution on to a pregrown stroma layer. No cytokines were present in these microwell LTC, which served as a read-out system for the frequency of CAFC in the growth factor-stimulated cell population. The CAFC frequency at week 5 was calculated from the percentage of negative wells in serial dilutions of plated cells. Only experiments in which the CD34 + HLA-DR low cells were at least 80% pure were included into this analysis.
As shown in Figure 7a , one in 406 CD34 + HLA-DR low cells stimulated with FL, IL-6 and SCF formed one cobblestone area in this assay (summarized in Table 1 ). If IL-3 was added to these factors, the frequency was decreased 2.5-fold. Furthermore, stimulation with a combination consisting of IL-3, IL-6 and SCF resulted in a 3.3-fold reduction. For statistical analysis, confidence intervals of the regression lines were calculated. The differences between FL, IL-6 and SCF versus IL-3-containing combinations were significant in one experiment, while in another experiment with cells from a different patient the 95% significance level was missed by a small margin (Table 1) . In both experiments, stimulation with a fivefactor combination consisting of FL, IL-6, SCF, LIF and IL-11 led to significantly higher CAFC frequencies than either IL-3-containing combination (Table 1) . These results suggest that primitive progenitor cells expanded with IL-3-containing combinations display reduced longterm culture-initiating (LTC-IC) capacity, which is partially restored by FL.
If expansion of CD34
+ HLA-DR low cells by the respective cytokine combinations is taken into account, the differences of total CAFC numbers are less marked. FL improved the generation of CAFC if added to the combination of IL-3, IL-6 and SCF (Figure 7b) .
Interestingly, addition of LIF and IL-11 to a factor combination consisting of FL, IL-6 and SCF increased the frequency of cobblestone areas significantly. As compared with untreated CD34 + HLA-DR low cells, analyzed by the time of cell separation, there was no significant reduction of CAFC frequencies in cells stimulated with the five cytokines (Table 1) . Furthermore, the absolute number of CAFC generated from CD34 
Retroviral transduction of CAFC
For transfer of a human MDR1 cDNA to hematopoietic cells, supernatant from a PA317-based amphotropic virus producer cell clone was used. This clone displayed titers between 3 × 10 6 and 2 × 10 7 colony-forming units/ml. CD34 + HLA DR low cells were transduced in suspension cultures on fibronectin-coated dishes with 11 consecutive rounds of supernatant supplemented with cytokine cock- Summary of CAFC frequencies in the expanded cell populations as shown in Figure 7a . Cells were analyzed by the time of immunoseparation, and after 5 days in tissue culture in the presence of cytokines as indicated. 95% confidence intervals were calculated from regression analysis.
Gene Therapy tails as indicated (estimated multiplicity of infection 300-1200). After 6 days, cells were harvested and plated at very low frequencies on to pregrown stroma. A frequency of less than one CAFC in seven to 10 wells reduces the probability of two different CAFC being in the same well to 1-2%. No drug selection was applied, which would have enriched for transduced cells. Five to 6 weeks later, adherent cells from wells in which a single cobblestone area was detected were harvested and analyzed by polymerase chain reaction (PCR) for the presence of ␤-actin and MDR1 cDNA. The MDR1-specific primers did not amplify the endogenous MDR1 gene because they spanned an intron. As a control, the contents of wells that had subjected to identical conditions without exposure to viruses were analyzed in each experiment.
The results are summarized in Table 2 , and a typical experiment is shown in Figure 8 (exp 3, stimulation with IL-3, IL-6, and SCF). Growth stimulation of CD34 + HLA-DR low cells with either FL or IL-3 combined with SCF and IL-6 during the transduction period resulted in comparable gene transfer frequencies to the progeny of CAFC. Both cytokine combinations facilitated integration of MDR1 cDNA in high numbers of CAFC-derived cells (mean of three independent experiments: 56.6-68.6%). In one experiment, which included also the five-factor combination (FL, SCF, IL-6, LIF and IL-11), transduction frequencies of greater than 80% were observed. In summary, the majority of CAFC was transduced with an MDR1 cDNA under conditions that do not necessarily include IL-3.
Discussion
We have shown that purified primitive human hematopoietic progenitor cells (CD34 + HLA-DR low Rho low ) from peripheral blood can be efficiently transduced under stroma-free culture conditions with conventional, amphotropic retroviruses. Retroviruses similar to the Harvey sarcoma virus-based vector pHaMDR1/A, which was packaged in PA317 cells, have been instrumental in preclinical and clinical MDR1-gene transfer studies.
2,25-31
Such amphotropic viruses can facilitate efficient MDR1 gene transfer to murine hematopoietic cells and to human clonogenic progenitors. 27, 29 However, high retroviral titers do not ensure efficient gene transfer to primitive human hematopoietic cells because of their quiescence and low numbers of receptors for amphotropic viruses. 15, 32 Thus, frequencies of transduced LTC-IC have usually been lower than of lineage-committed colony-forming progenitors. [33] [34] [35] Recently published protocols that employ the addition of stroma-free supernatant from amphotropic viruses to hematopoietic cells have allowed for relatively low gene transfer frequencies of 5-22% into LTC-IC-derived cells.
14,33-37 Moreover, in two recent studies, LTC-IC from purified primitive cord blood cells (CD34 + CD38 − ) could not be transduced when Moloneybased amphotropic vectors were used for gene transfer. 14, 34 This was achieved only with pseudotyped, gibbon ape leukemia virus-derived vectors.
The improved frequency of retrovirally transduced CAFC in our study is presumably due to extended transduction with multiple additions of viral supernatant, which was possible because primitive cell properties were preserved for a long period. Multiple rounds of HLA-DR low cells were transduced in suspension cultures with retroviral supernatant supplemented with growth factors as described in the text. After 6 days, cells were plated at limiting dilution on to a pregrown layer of irradiated stroma cells. After 5 weeks, the content of wells containing a single CAFC was trypsinized and harvested. Cells were lysed, and a 311-base pair fragment of MDR1 cDNA was amplified by PCR. Amplification of the correct sequence was confirmed by Southern hybridization with an MDR1 oligonucleotide fragment. As a negative control, cells were cultured without exposure to retroviruses under otherwise identical conditions. 
HLA-DR low cells were transduced with retroviral supernatant in 5-day suspension cultures in the presence of IL-3, IL-6 and SCF. They were then transferred in limiting dilution on to a pregrown layer of irradiated stromal cells. Cells were grown as LTC for 5 to 6 weeks. Wells that contained single cobblestone areas were trypsinized, and DNA was prepared. First, a fragment of the beta-actin gene was amplified by PCR (positive control). If beta-actin could be amplified, a PCR was performed with primers specific for the human MDR1 cDNA. PCR products were blotted on to Nylon membranes and hybridized with an MDR1 probe that had been generated by PCR. M, molecular weight marker; P, positive control; 1-26, DNA from individual wells containing CAFC-derived cells after transduction; L, lysis buffer as negative control; N1-12, negative controls (non-transduced cobblestone area containing wells).
transduction have little influence on gene transfer rates to clonogenic cells, but improve transduction of LTC-IC. In addition, fibronectin increases the gene transfer to hematopoietic cells, 38 and a high multiplicity of infection was accomplished by depletion of more differentiated target cells (CD34 + HLA-DR + ). 39 A different approach for improvement of MDR1 gene transfer is the use of pregrown stromal layers as an alternative source of growth factors. 37 However, the function of autologous stroma from patients undergoing chemotherapy may be impaired, 40 while allogeneic donor stroma bears the risk of transmitting infections. Thus, it would be advantageous to maintain and transduce early hematopoietic cells in stroma-free cultures.
Transfer of the human MDR1 gene to hematopoietic stem/progenitor cells is being investigated in the clinic. While protection from chemotherapy-related leukocytopenia was demonstrated in animal models, 41, 42 it still awaits clinical confirmation. A second potential application is based on enrichment of MDR1 transduced cells after exposure to anticancer drugs. The MDR1 gene can be co-expressed with otherwise non-selectable genes that correct genetically determined disease. 43, 44 Selection with substrates of P-glycoprotein is expected to restore expression of both genes if the expression levels in bone marrow decline. This has been shown in cultured hematopoietic cells transduced with a vector that corrected for Gaucher's disease. 45 For both applications, however, it is mandatory that initially a high number of hematopoietic stem cells are transduced with retroviruses.
Optimization of growth conditions for transduction of hematopoietic progenitor and stem cells is currently under investigation by several groups with various cytokine combinations being used. Hennemann et al 39 reported similar transduction frequencies into LTC-IC when cells were stimulated with either FL, SCF, hyper-IL-6 and thrombopoietin (TPO), or with FL, SCF, IL-3, IL-6 and granulocyte colony-stimulating factor. In recent reports, sustained expansion of hematopoietic cells at different stages of maturation, including LTC-IC, was accomplished by SCF and TPO. 20 Addition of FL to the latter two factors resulted in efficient stimulation of early hematopoietic cells. 46, 47 A similar combination with the inclusion of IL-6 allowed for high levels of repopulation of NOD/SCID mice with human hematopoietic cells. 48 Schiedlmeier et al 49 found comparable levels of engraftment in NOD/SCID mice if cells were cultured in the presence of TPO, SCF and FL, or with IL-3, IL-6, SCF and FL. Comparable results, showing general improvement of gene transfer techniques, were obtained in other recent studies in NOD/SCID mice or in non-human primates. 50, 51 That IL-3-treated hematopoietic stem cells are capable of repopulating bone marrow has been demonstrated in murine and in large-animal models. 17, 19, 28, 47, [49] [50] [51] [52] [53] Several reports, however, indicate that engraftment of hematopoietic cells exposed to IL-3 is relatively poor. [22] [23] [24] In a recent study, stimulation of murine bone marrow with IL-3 and IL-11 reduced transduction of long-term repopulating cells whereas SCF, FL and TPO led to efficient stem cell transduction. 54 Whether IL-3 impairs gene transfer and the capacity of hematopoietic stem cells to repopulate bone marrow remains controversial. Technical differences of expansion in culture may contribute to these conflicting results. We did not observe a detrimental effect of IL-3 or IL-11 on gene transfer to CAFC, whereas IL-3 (but not IL-11) exerted marked effects on the primitive Rho low phenotype. FL preserves the ability of human progenitors to sustain human hematopoiesis in mice after retroviral transduction and has been useful together with other cytokines. 18, 47, [55] [56] [57] However, no single optimal protocol has been established for transduction of primitive human hematopoietic cells so far.
Loss of stem cell properties during the process of gene transfer is a major obstacle to long-term gene expression, but no valid parameter for assessment of differentiation ex vivo is commonly established. Results presented here suggest that rhodamine-123 extrusion is a highly sensitive indicator for differentiation of primitive PBPC. Hematopoietic stem cells, which are highly enriched in longterm bone marrow repopulating cells and LTC-IC, accumulate low amounts of P-glycoprotein substrates, rhodamine-123 and Hoechst 33342. 8 Accordingly, Rho low cells sustain long-term in vitro hematopoiesis while Rho high cells have no CAFC activity. 58 P-glycoprotein expression is down-regulated upon myeloid and erythroid differentiation. 10, 11, 59 Hence, loss of the Rho low phenotype in the presence of IL-3 is consistent with the onset of differentiation. Analysis of rhodamine-123 extrusion may thus be useful for further optimization of growth conditions. We found that reduction of the CAFC frequency due to IL-3 treatment was less closely associated with changes of surface antigens, CD34 and HLA-DR. This may reflect the broader range of cells expressing these antigens in normal hematopoietic tissues. For instance, CD34 is expressed on 5% of normal bone marrow cells and on 1.5-4.5% of light-density bone marrow cells, and is thus not restricted to the small compartment of pluripotent stem cells. 60, 61 It should be noted that the rhodamine-123 extrusion experiments were performed with untransduced cells and thus represent a physiologic response to cytokine stimulation. In our experiments, rhodamine-123 extrusion was unsuitable for detection of MDR1-transduced cells because the function of endogenous P-glycoprotein could not be distinguished from the function of the transgene.
The conclusion that IL-3 induces differentiation in culture is further supported by reduced CAFC frequencies, which were observed in primitive PBPC stimulated with IL-3-containing cytokine combinations. The number of late colonies in the CAFC bioassay is closely correlated with the number of bone marrow-repopulating cells following transplantation and with engraftment in SCIDhubone transplantation models. 13, 46 However, as opposed to CAFC assays, gene transfer frequencies to single primitive progenitor/stem cells are more difficult to assess in animal models.
IL-3 containing cytokine combinations have been used in many clinical gene transfer protocols because they facilitate large augmentation of cell numbers ex vivo. In Gene Therapy our study, this was associated with reduced CAFC frequencies as compared with FL, IL-6 and SCF (+/− IL-11, LIF). Moreover, the total numbers of CAFC were higher following stimulation with a five-factor combination without IL-3, than with the IL-3-containing cocktails. We conclude that a major proportion of cells generated by expansion with IL-3 consists of more differentiated progenitors rather than primitive cells. Taken together, IL-3 is not necessarily required for efficient growth stimulation of primitive PBPC.
The transduction protocol described here maintains an immature phenotype in the majority of cells for at least 5 days. FL was particularly beneficial for preservation of an immature phenotype because it could partially overcome the differentiation-inducing activity of IL-3 in combination with IL-6 and SCF. We have shown that primitive hematopoietic progenitor cells can be efficiently stimulated to proliferate ex vivo without IL-1 or IL-3. Upon addition of LIF and IL-11 the number of CAFC generated in culture was increased without major changes of the primitive Rho low phenotype. Other early-acting factors may be useful to further optimize maintenance of CAFC in culture.
In conclusion, we have developed a protocol that facilitates efficient transduction with amphotropic retroviruses of primitive human progenitor cells mobilized into peripheral blood. Further studies in animal models should determine whether preservation of a primitive phenotype during the transduction procedure ex vivo will improve long-term expression of transferred genes.
Materials and methods
Preparation of peripheral blood progenitor cells Following informed consent, patients suffering from neoplastic disease were treated with 4-11 g/kg filgrastim (Amgen, Munich, Germany) daily after chemotherapy. Once leukocyte counts had passed nadirs, and CD34 + cell concentrations in peripheral blood exceeded 10/l, nucleated cells were collected using Cobe Spectra equipment (Lakewood, CO, USA). Alternatively, stem cell collections from filgrastim-treated donors were used. Cells were washed with phosphate buffered saline (PBS) containing 0.6% anticoagulants citrate dextrose-formula A (ACD-A; Fresenius, Bad Homburg, Germany) and 1% human albumin. They were then labeled with CD34-MultiSort microbeads (Miltenyi, Bergisch Gladbach, Germany), and immunoseparated using a VarioMacs device (Miltenyi) according to the manufacturer's instructions.
Anti-CD34-coated microbeads were detached with MultiSort Release Reagent (Miltenyi). Cells were then stained for 30 min with monoclonal antibodies to HLA-DR conjugated to fluorescein isothiocyanate (FITC; Becton Dickinson, Heidelberg, Germany) at 0.5 g/10 6 cells, followed by incubation with anti-FITC microbeads at 20 l/10 7 cells. HLA-DR-FITC labeled cells were depleted with a VarioMacs device.
Aliquots of the separated cells were then reanalyzed using flow cytometry. They were restrained with phycoerythrin-conjugated HPCA-2 antibodies (anti-CD34), and FITC-labeled anti-HLA-DR antibodies (both from Becton-Dickinson, used at 0.5 g/10 6 cells). Isotypeidentical control antibodies (Becton Dickinson or Pharmingen, Hamburg, Germany) were used at identical con-centrations. Data acquisition and analysis were performed with a FACSCalibur cytometer (Becton Dickinson).
Rhodamine-123 extrusion
Active rhodamine-123 efflux was determined essentially as described. 28 Briefly, hematopoietic cells were first incubated for 30 min at 37°C in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Eggenstein, Germany) without phenol red, supplemented with 5% fetal bovine serum (FBS; Seromed, Berlin, Germany) and 1 g/ml rhodamine-123 (Sigma, Deisenhofen, Germany). Thereafter, cells were spun down and resuspended in the same medium in the absence of rhodamine-123, with or without 20 m verapamil (Sigma). After a 3-h incubation at 37°C, cells were centrifuged again. The supernatants were removed except for a remaining volume of 400 l and, after resuspension of cells, tubes were transferred to ice. Cellular fluorescence was immediately assessed by flow cytometry.
Suspension cultures of hematopoietic cells
Immunoseparated cells were transferred to Myelocult H5100 (Stem Cell Technologies, Vancouver, BC, Canada) and grown for 5 days if not indicated otherwise. Recombinant human cytokines were added at the time of initiation of cultures. IL-3 and IL-6 (both from Life Technologies) were used at 10 ng/ml, SCF at 10 ng/ml, IL-11 at 10 ng/ml, leukemia inhibitory factor (LIF) at 1 ng/ml (all from Pharmingen) and FL (a gift from Immunex, Seattle, WA, USA) at 100 ng/ml. Except for LTC experiments, cells were always grown at 37°C in a humidified atmosphere with 5% CO 2 .
Retroviral transduction in stroma-free cultures Retroviral producer cells were a generous gift of Dr Gottesman, National Cancer Institute, NIH, Bethesda, MD, USA. The producer cell clone, designated 3P1, which had been developed by transfection of PA317 packaging cells with plasmid pHaMDR1/A 62 were maintained in 30 ng/ml vincristine (Sigma). Titration was performed as described. 63 For transduction of hematopoietic cells, 3P1 cells were pregrown to subconfluency in DMEM, 18 h before the experiments, the supernatant was replaced by Iscove's modified Dulbecco's medium containing 20% FBS, penicillin and streptomycin. The virus-containing supernatant was harvested, passed through a 0.45 m filter (Millipore, Bedford, MA, USA), and supplemented with cytokines and 4 g/ml polybrene (Sigma).
Immunomagnetically separated CD34 + HLA-DR low cells were first prestimulated with growth factors for 24 h. The cell suspension were spun down, resuspended at 1 × 10 5 cells/ml in filtered viral supernatant containing growth factors and polybrene, and transferred to dishes that had been coated with 50 g/ml fibronectin (Boehringer, Mannheim, Germany). Eleven consecutive replacements of viral supernatant were carried out within 144 h, the first being performed after the prestimulation period. Cells were then transduced twice daily with 6-8 h intervals. Thereafter, cells were harvested and further analyzed by flow cytometry or LTC assays. As a negative control, CD34
+ HLA-DR low cells were cultivated at identical conditions while no retroviruses were present.
Cell cycle analysis Cells were washed with PBS, then resuspended in 200 l PBS. 2 ml of ice-cold 70% v/v ethanol in water was added. After vigorous mixing, they were incubated for 30 min at 4°C. Cells were then spun down and resuspended in PBS containing 50 g RNase A (Qiagen, Hilden, Germany) and 20 g propidium iodide (Sigma). After a 30-min incubation at room temperature, the DNA content was determined by flow cytometric analysis. Limiting dilution analysis of cobblestone area-forming cells (CAFC) CAFC frequencies were calculated by a limiting dilution assay described. 64 Briefly, stroma layers generated from bone marrow of healthy volunteers, were irradiated after reaching confluence (15 Gy), and distributed into 96-well plates. Serial dilutions of cytokine-treated CD34 + HLA-DR low cells or, as a control, unstimulated cells were added to the stroma layers. Cells were grown at 33°C in 5% CO 2 in a humidified incubator using Myelocult H5100 without recombinant cytokines (Stem Cell Technologies) supplemented with 10 m hydrocortisone succinate (Sigma). Cultures were fed weekly by replacing half of the supernatant with fresh medium. After 35 days, wells containing cobblestone areas were enumerated by inverted microscopy. The frequency of CAFC was calculated from the percentage of negative wells with the use of 'L-Calc Software for Limiting Dilution Analysis' (Stem Cell Technologies).
Analysis of cell division
For analysis of proviral sequences integrated into cells derived from a single CAFC, CD34
+ HLA-DR low cells were harvested from retrovirus-containing medium, washed and plated at very low frequencies on to the pregrown stroma layer. After the LTC period, wells containing a single cobblestone area were rinsed with PBS and trypsinized. The content of each well was kept frozen at −80°C until analysis by PCR.
Analysis of MDR1 cDNA from microwell LTCs
Cells from single wells containing cobblestone areas were incubated for 1 h at 56°C in 50 l of lysis buffer containing 0.5% NP-40, 0.5% Tween 20, 10 mm Tris pH 8.3, 50 mM KCl, 0.01% gelatine, 2.5 mm MgCl 2 and 60 g/ml proteinase K (Life Technologies). Lysates were heated to 95°C for 10 min and stored at −80°C.
Ten l of cell lysate were used as template for PCR, which was performed with the AmpliTaq Gold DNA Polymerase (Perkin-Elmer, Weiterstadt, Germany). First, a fragment of 295 base-pairs from the beta-actin gene was amplified with primers BACT3Ј, 5Ј-CAG CGG AAC CGC TCA TTG CCA ATG-3Ј (forward) and BACT5Ј, 3Ј-TCA CCC ACA CTG TGC CCA TCT ACG-5Ј (reverse). After an initial denaturation step at 95°C, 40 cycles at 94°C/57°C/72°C were performed, followed by an extension at 72°C for 7 min. PCR products were separated on a 1.4% agarose gel and visualized by ethidium bromide staining. Lysates from which the beta-actin gene frag-ment could be amplified were then analyzed for the presence of human MDR1 cDNA.
Primers TL9, 5Ј-TTC AAA CTT GTC ACA ATG CAG ACA GCA GGA-3Ј (forward) and TL10, 3Ј-GGT TGC AGG CCT CCA TTT ATA ATG GCA CAA-5Ј (reverse) were used for detection of MDR1 cDNA, yielding a fragment of 311 base-pairs. The conditions for PCR were similar: 40 cycles at 94°C/56°C/72°C were performed. The specificity of amplified MDR1 cDNA fragments was confirmed by Southern blotting. To do this, PCR products were transferred to a nylon membrane (Boehringer Mannheim) and hybridized to a 69-mer oligonucleotide probe. This probe had been generated by amplification of human MDR1 cDNA with primers TL9 (forward) and TL8, 3Ј-CCA AGG CAT CAA TTT CAC TTT TGG A-5Ј (reverse). The DIG DNA Labeling and Detection Kit (Boehringer Mannheim) was used for non-radioactive labeling of the probe and detection of hybridized DNA on the nylon membrane.
